Johnson & Johnson's CEO has explicitly ruled out pursuing GLP-1 or obesity-related drugs, choosing instead to concentrate resources on cancer — a category that has been driving the bulk of J&J's MedTech and Innovative Medicine growth. With FY revenue at $94.2B (+6.0% YoY), a 67.9% gross margin, and $11.03 diluted EPS, J&J is already executing well without needing exposure to the crowded obesity race.
The strategic pass on obesity drugs means J&J won't chase NVO or LLY on that front, but it also avoids the pipeline risk and pricing scrutiny that comes with that market. The question is whether oncology alone can sustain the premium multiple the market may expect — key catalysts to watch include upcoming oncology data readouts and any M&A activity in the cancer space.